GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.540
-0.080 (-4.94%)
At close: Jul 16, 2026, 4:00 PM EDT
1.461
-0.079 (-5.16%)
Pre-market: Jul 17, 2026, 8:51 AM EDT
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,727,000
Market Cap
2.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2024 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2023 | 4 | 3 | 300.00% | 4 | 0 |
| Dec 31, 2022 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 26 |
| VivoSim Labs | 14 |
| Decoy Therapeutics | 11 |
| Galmed Pharmaceuticals | 6 |
| Creative Medical Technology Holdings | 4 |
| Oragenics | 3 |
| SciSparc | 3 |
GRI News
- 4 weeks ago - GRI Bio announces U.S. FDA granted ODD to GRI-0621 - TheFly
- 4 weeks ago - GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 4 weeks ago - GRI Bio granted FDA orphan designation for tazarotene - TheFly
- 2 months ago - GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire
- 2 months ago - GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline - GlobeNewsWire
- 2 months ago - GRI Bio Quarterly report: Q1 2026 - Filings
- 2 months ago - GRI Bio Earnings release: Q1 2026 - Filings
- 3 months ago - GRI Bio receives UAE patent allowance for inflammatory disease treatments - TheFly